TP53 and hepatocellular carcinoma: More data was collected from TCGA across different cancer types (including hepatocellular carcinoma, lung squamous cell carcinoma, lung adenocarcinoma, colon adenocarcinoma, stomach adenocarcinoma and ovarian serous cystadenocarcinoma), and a trend of increased miR-766 expression in p53 mutant groups was found (Supplementary Figure 1B).